{
    "ticker": "HEAT",
    "name": "Heat Biologics, Inc.",
    "description": "Heat Biologics, Inc. is a clinical-stage biotechnology company dedicated to developing novel immunotherapies for cancer and infectious diseases. Founded in 2008, Heat Biologics leverages its proprietary Immune PanAntigen Cytotherapy (IPC) platform, designed to stimulate and enhance the body's immune response against tumors. The company's leading product candidates include the therapeutic vaccine, HS-110, which targets non-small cell lung cancer (NSCLC) and aims to improve patient outcomes by activating the immune system to recognize and attack cancer cells. With a commitment to advancing cancer treatment through innovative science, Heat Biologics is focused on expanding its pipeline of immuno-oncology therapies and exploring synergistic combinations with other treatment modalities, such as checkpoint inhibitors. The company actively collaborates with leading research institutions and clinical centers to further its mission of developing effective therapies that can significantly improve patient survival rates and quality of life. As the landscape of cancer therapy evolves, Heat Biologics is positioned to be at the forefront of innovation, striving to bring hope to patients facing devastating diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2008",
    "website": "https://www.heatbio.com",
    "ceo": "Jeffrey Wolf",
    "social_media": {
        "twitter": "https://twitter.com/heatbio",
        "linkedin": "https://www.linkedin.com/company/heat-biologics/"
    },
    "investor_relations": "https://www.heatbio.com/investors",
    "key_executives": [
        {
            "name": "Jeffrey Wolf",
            "position": "CEO"
        },
        {
            "name": "David Koos",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Vaccines",
            "products": [
                "HS-110"
            ]
        }
    ],
    "seo": {
        "meta_title": "Heat Biologics, Inc. | Innovative Immunotherapies for Cancer",
        "meta_description": "Explore Heat Biologics, Inc., a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. Discover their innovative approach to cancer treatment.",
        "keywords": [
            "Heat Biologics",
            "Immunotherapy",
            "Cancer Treatment",
            "Biotechnology",
            "HS-110"
        ]
    },
    "faq": [
        {
            "question": "What is Heat Biologics known for?",
            "answer": "Heat Biologics is known for its innovative immunotherapies, particularly its therapeutic vaccine HS-110 for cancer treatment."
        },
        {
            "question": "Who is the CEO of Heat Biologics?",
            "answer": "Jeffrey Wolf is the CEO of Heat Biologics, Inc."
        },
        {
            "question": "Where is Heat Biologics headquartered?",
            "answer": "Heat Biologics is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What are Heat Biologics' main products?",
            "answer": "Heat Biologics' main product is the therapeutic vaccine HS-110 for non-small cell lung cancer."
        },
        {
            "question": "When was Heat Biologics founded?",
            "answer": "Heat Biologics was founded in 2008."
        }
    ],
    "competitors": [
        "CRMD",
        "XBIO",
        "KOSK"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}